articleJournal of Thoracic OncologyMar 1, 2025BRONZE OA

4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study

JYJ.C-H. YangYJYoon Jun KimSLSH LeeBLB. LiuYOY.V. Ostapenko

National Taiwan University · Seoul National University Bundang Hospital · +21 more institutions

Indexed incrossref

Abstract

No abstract available for this paper.

Citation impact

43
total citations
FWCI
54.48
Percentile
100%
References
0
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Osimertinib
  • Medicine
  • Overall survival
  • Oncology
  • Mutant
  • Internal medicine
  • Genetics
  • Adenocarcinoma
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.

Funding